Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
C.NINE: Drill Rig Mobilization for the Wedge 10,000m Drill Program & Targeting New High Grade Copper Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

IIROC Trading Resumption - ACST

Canada NewsWire December 24, 2019

Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

GlobeNewswire December 23, 2019

IIROC Trading Halt - ACST

Canada NewsWire December 23, 2019

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

GlobeNewswire November 26, 2019

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

Newsfile November 25, 2019

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre's Novel Mechanism of Action in Diabetes

GlobeNewswire November 18, 2019

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

GlobeNewswire November 13, 2019

Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

GlobeNewswire November 7, 2019

Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

GlobeNewswire November 6, 2019

Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®

GlobeNewswire November 4, 2019

Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire October 1, 2019

Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

GlobeNewswire September 30, 2019

Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

GlobeNewswire September 9, 2019

Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

GlobeNewswire September 4, 2019

Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

GlobeNewswire August 28, 2019

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

GlobeNewswire August 14, 2019

Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference

GlobeNewswire August 9, 2019

Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call

GlobeNewswire August 7, 2019

Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital

GlobeNewswire July 25, 2019

Acasti Pharma Provides Fiscal 2019 Year-End Business Update

GlobeNewswire June 26, 2019

Podcasts